India, March 13 -- Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Cevimeline Hydrochloride Capsules 30 mg, (USRLD: Evoxac' Capsules, 30 mg).Cevimeline Hydrochloride Capsules 30mg are indicated for the symptomatic treatment of dry mouth (xerostomia) associated with Sj'gren's syndrome. Cevimeline is a muscarinic receptor agonist that stimulates salivary secretion.Cevimeline hydrochloride 30 mg capsules will be produced at the Group's manufacturing facility at SEZ-II, Ahmedabad.Cevimeline Hydrochloride Capsules 30mg had annual sales of USD 26.9 mn. (IQVIA MAT Jan-26).
Published by HT Digital Content Services with permission from Pivotal Sources....